AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04575051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Engage Model
Description: The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT06447987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV
Study NCT06447987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET
Study NCT06447987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06447987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06447987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05616988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological-clinical intervention with three days of expressive writing by Pennebaker
Description: The psychological-clinical intervention involves five interviews with three days of expressive writing by Pennebaker. During the psychological-clinical interviews the following aspects will be explored:~* Emotions and expectations related to the breast reconstruction process.~* Feelings related to the perception of one's own body image to promote an integration between the image of one's body and the aspects related to one's own identity and femininity.~* Thoughts and feelings related to one's relational and social life.~Expressive writing is a technique devised by Pennebaker (1986), who states that expressing deeper thoughts and feelings through writing can improve the physical and psychological health of the individual. The writing task consists of writing about a traumatic experience or a significant event for the person, for a controlled period (usually 15-30 minutes) and on consecutive days (from 2 to 3 days).
Study NCT06530862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESWT+stretching exercises
Description: Participants in this group will receive ESWT treatment
Study NCT06530862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling+stretching exercises
Description: Participants in this group will receive Dry needling treatment
Study NCT04699279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
Study NCT05441072 — intervention group
Intervention type: DEVICE
Intervention: BulbiCam
Description: The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs.
Study NCT04885062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Ring
Description: The Belun Ring sensor will be applied to the proximal phalanx of the index finger in the non-dominant hand of the participating individuals prior to their sleep onset in the sleep lab and will be removed upon awakening at the end of the sleep period on the following morning. The attended in-lab sleep study will be performed simultaneously in a standard fashion.
Study NCT04885062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG
Description: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
Study NCT06171191 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Move-ARound And Get Active
Description: The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
Study NCT06171191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move-ARound And Get Active
Description: The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
Study NCT06097312 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
Study NCT06572982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 300 mg Film coated tablets
Study NCT06266338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV q 3 weeks
Study NCT05722288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05722288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05722288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive nutritional counseling
Study NCT05722288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06266338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg PO daily
Study NCT05363566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway divice
Description: inserted airway device
Study NCT06486467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluid challenge (cristalloids) OR passive leg raising
Description: Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition
Study NCT05093036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variations in PrEP care delivery at public health services
Description: Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
Study NCT05722288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05722288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05722288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05722288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Undergo time-restricted eating
Study NCT06574763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48/Carboplatin
Description: RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W
Study NCT06576154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 1000 MG
Description: * Medication: Cefazolin~* Dosage: 1 gram~* Administration Timing: A single dose will be administered preoperatively.
Study NCT06529445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose VC004 Capsules
Description: VC004 Capsules qd per period, for two periods
Study NCT06529445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Median Dose VC004 Capsules
Description: VC004 Capsules qd per period, for two periods
Study NCT06529445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose VC004 Capsules
Description: VC004 Capsules qd per period, for two periods
Study NCT04819269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tivanisiran sodium ophthalmic solution
Description: 1 drop in the affected eye(s) once daily
Study NCT04819269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: 1 drop in the affected eye(s) once daily
Study NCT04814329 — intervention group
Intervention type: OTHER
Intervention: genetic characteristic
Description: the underlying genetic characteristics that prodicting response
Study NCT05751473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study.
Study NCT05751473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EAP Treatment as Usual (TAU)
Description: Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study.
Study NCT06470854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Dexmedetomidine
Description: Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
Study NCT06470854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral greater occipital nerve block
Description: The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
Study NCT05252767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Tools
Description: Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
Study NCT05252767 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational Guide
Description: Control participants will receive a brief educational guide about pain management.
Study NCT06325722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate Diet
Description: Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
Study NCT06325722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat Diet
Description: Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
Study NCT05297500 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-12)
Study NCT06188806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADDUKTOR CANAL BLOCK
Description: All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
Study NCT06188806 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CONTROL GROUP
Description: No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
Study NCT05384756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV
Study NCT05384756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT
Study NCT05384756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo TMLI
Study NCT05384756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Medication to prevent the development of graft-versus-host disease (GVHD)
Study NCT05414682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIND+SOUL Diet
Description: The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
Study NCT05823376 — intervention group
Intervention type: DRUG
Intervention: Avatrombopag
Description: Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
Study NCT06481410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue Intervention Group
Description: In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
Study NCT06481410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Control Group
Description: In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
Study NCT06464718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fortibone
Description: Participants were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA).
Study NCT06464718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewable Tablet
Description: calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily
Study NCT05312463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongjiang granule
Description: Tongjiang granules, 1 bag / time, 3 times / day.
Study NCT05312463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tongjiang granule simulant
Description: Tongjiang granule simulant,1 bag / time, 3 times / day.
Study NCT04707469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
Study NCT04707469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
Study NCT06202105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Gastrectomy with laparoscopic approach
Study NCT06202105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastrectomy
Description: Gastrectomy with laparoscopic approach
Study NCT04146714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substance use questionnaire
Description: Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
Study NCT04146714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity questionnaire
Description: Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
Study NCT05897476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
Study NCT06037460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Description: * 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24
Study NCT06037460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: HAQ, SF-36, FACIT-Fatigue score
Study NCT06037460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: HAQ, SF-36, FACIT-Fatigue score
Study NCT06037460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Additionnal blood samples for immunomonitoring
Study NCT06037460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Additionnal blood samples for immunomonitoring
Study NCT06037460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18FDG PET scan
Description: PETVAS calculation (to be performed between W0 and W8) (optional).